| Identification | Back Directory | [Name]
2-(4-Aminophenyl)quinoline | [CAS]
22191-97-5 | [Synonyms]
4-(2-quinolyl)aniline
4-quinolin-2-ylaniline
2-(4-Aminophenyl)quinoline
[4-(2-quinolyl)phenyl]amine
4-(2-Quinolinyl)benzenamine
(4-Quinolin-2-ylphenyl)amine
Benzenamine, 4-(2-quinolinyl)-
BF-170 hydrochloride >=98% (HPLC), solid | [Molecular Formula]
C15H12N2 | [MDL Number]
MFCD08705340 | [MOL File]
22191-97-5.mol | [Molecular Weight]
220.27 |
| Hazard Information | Back Directory | [Uses]
BF-170 is a selective tau fibril binding agent with an EC50 of 221 nM. It exhibits good blood-brain barrier permeability, and after intravenous injection in mice, the concentration in brain tissue reaches 9.1% ID/g within 2 minutes (with a brain clearance rate of 0.25% ID/g after 30 minutes). BF-170 can be used as a probe for tau protein pathology imaging in Alzheimer's disease (AD). It plays an important role in early-stage AD research and holds potential for imaging studies of tau-related neurodegenerative diseases[1]. | [Biological Activity]
BF-170 is a new probe for neurofibrillary tangles (tau fibrils). It exhibits greater binding affinity to tau than to Aβ fibrilsEC50 = 221 nM vs. EC50 = 786 nM (Ki for Aβ > 5,000 nM). BF-170 demonstrates fast clearance from the brain; clearly visualizes neurofibrillary tanglesneuropil threadsand paired helical filament-type neuritis. BF-70 may become one of the candidate compounds for in vivo imaging of tau pathology associated with Alzheimerμs disease and is a useful tool in distinguishing among tau and Aβ fibrils specifically in AD. | [References]
[1] Okamura N, et al. Quinoline and benzimidazole derivatives: candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci. 2005 Nov 23;25(47):10857-62. DOI:10.1523/JNEUROSCI.1738-05.2005 |
|
| Company Name: |
Energy Chemical
|
| Telephone: |
400-0056266 |
| Website: |
www.energy-chemical.com |
| Company Name: |
TargetMol
|
| Telephone: |
400-821-0310 15002144251 |
| Website: |
www.targetmol.cn/ |
|